INDUCTION OF KILLER-CELLS FROM LYMPHOCYTES IN PLEURAL EFFUSION OF ADVANCED LUNG-CANCER PATIENTS

被引:9
作者
INOUE, Y
SHIJUBO, N
UEDE, T
机构
[1] SAPPORO MED COLL,DEPT INTERNAL MED,SECT 3,S-1,W-16,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN
[2] SAPPORO MED COLL,DEPT PATHOL,SECT 1,SAPPORO,HOKKAIDO 060,JAPAN
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1990年 / 81卷 / 10期
关键词
Autologous tumor stimulation; Cytotoxic T lymphocytes; Lung cancer; Pleural exudative lymphocytes;
D O I
10.1111/j.1349-7006.1990.tb03339.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We analyzed the phenotype and cytotoxic ability of pleural exudative lymphocytes (PLEL) which were obtained from 18 advanced lung cancer patients. Freshly isolated PLEL were mainly CD4(+) T cells and had weak natural killer, autologous tumor killing and lymphokine‐activated killer activities. After cultivation of PLEL with interleukin‐2, cytotoxicity of PLEL against autologous tumor cells was increased at 2 weeks, but it was remarkably reduced at 4 weeks. When PLEL were stimulated by mitomycin C‐treated autologous tumor cells during culture, autologous tumor killing activity of PLEL was significantly enhanced even after 4 weeks of cultivation. Cold target inhibition analysis and binding inhibition assays using monoclonal antibodies indicated that autologous tumor stimulation could induce major histocompatibility complex class I restricted cytotoxic T lymphocytes specific for autologous tumor cells in some cases. © 1990 Japanese Cancer Association
引用
收藏
页码:1012 / 1020
页数:9
相关论文
共 25 条
  • [1] BELLDEGRUN A, 1989, J IMMUNOL, V142, P4520
  • [2] BLANCHARD DK, 1988, CANCER RES, V48, P6321
  • [3] LYMPHOCYTE SUBPOPULATIONS AND T-CELL SUBSETS IN HUMAN ORAL-CANCER TISSUES - IMMUNOHISTOLOGIC ANALYSIS BY MONOCLONAL-ANTIBODIES
    HIRATSUKA, H
    IMAMURA, M
    KASAI, K
    KAMIYA, H
    ISHII, Y
    KOHAMA, GI
    KIKUCHI, K
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1984, 81 (04) : 464 - 470
  • [4] HOLLINSHEAD A, 1987, CANCER, V60, P1249, DOI 10.1002/1097-0142(19870915)60:6<1249::AID-CNCR2820600616>3.0.CO
  • [5] 2-I
  • [6] IBAYASHI Y, 1985, J IMMUNOL, V134, P648
  • [7] INOUE Y, 1989, 48TH P JPN CANC ASS, P268
  • [8] ITOH K, 1986, CANCER RES, V46, P3011
  • [9] KIKUCHI Y, 1986, J IMMUNOL, V136, P3553
  • [10] KON S, 1982, P JPN SOC IMMUNOL, V12, P36